CRISPR Therapeutics AG CRSP

CRISPR Therapeutics (CRSP) closed at $54.23, down 2.64% on the session and lagging broader indices which rose slightly. Over the past month the stock is down 6.18%, underperforming the Medical sector and the S&P. Ahead of the next quarterly report, CRSP is forecast to show an EPS of -$1.13, a 3.42% year-over-year improvement, with revenue of $9.53 million, up 971.24% from the prior year. For the full year, estimates call for -$4.58 per share on $30.59 million in revenue, up 29.21% and 771.54%, respectively. Analyst revisions have been modest; the stock holds a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry sits in the bottom third of 250+ industries (Rank 172). Negative near-term earnings with a large revenue uplift and modest revisions signal a mixed outlook.

CRISPR Therapeutics (CRSP) is a younger, research-focused biotech that recently gained its first product approval but remains unprofitable with heavy R&D burn. Vertex Pharmaceuticals (VRTX) is a cash-generating leader with a cystic fibrosis franchise and a growing pipeline, backing a broader program with CRSP. CRSP relies on Vertex to commercialize CASGEVY for sickle cell disease and transfusion-dependent beta-thalassemia, a setup that controls costs but creates revenue dependency. FY2025 revenue was about $3.5 million, down ~90% from the prior year, with a net loss near $582 million. Debt/Equity ~0.2x; current ratio ~13.3x; free cash flow negative ~$346 million. Vertex posted FY2025 revenue ~$12.1 billion, net margin ~32.7%, debt/Equity ~0.2x, current ratio ~2.9x, and free cash flow about $3.2 billion. Valuation implies CRSP is a high-growth bet; Vertex offers steadier cash flow. Vertex is favored for 2026, while noting CRSP’s potential amid losses and IP risk. CRSP's profitability risk, revenue dependence on Vertex, and ongoing IP/dilution concerns could materially alter its trajectory.

CRISPR Therapeutics (CRSP) trades near $59, about 48% below the Wall Street consensus of $87.56. Piper Sandler’s Edward Tenthoff has a Street-high target of $110, implying roughly 86% upside. CASGEVY revenue rose 151% YoY to $76M in Q2, but CRSP stock is down about 5% over the past year as investors await a sustained commercial ramp. CRSP remains the only peer with an approved, revenue-generating product; NTLA and BEAM show higher upside but lack current commercial programs. Full-year 2025 revenue was $3.51M; Q4 2025 revenue fell 97.5% YoY to $864K as Vertex deferral expired and collaboration expense rose; Q1 2026 revenue missed by ~66%. Cash burn remains heavy, but a $2.56B pro forma cash balance from a $600M convertible note funds R&D for years. The bull case hinges on CASGEVY ramp and pipeline readouts; bear case on lumpiness and ongoing losses. Strong near-term catalysts from CASGEVY growth and a large cash runway could meaningfully alter CRSP's trajectory, though execution risk and revenue volatility cap upside.

Q2 13F filings show billionaire Ken Fisher's Fisher Asset Management opened new positions in CRISPR Therapeutics (CRSP) and Coinbase Global (COIN). The fund bought 77,960 CRISPR shares (~$4.25 million) and 9,714 Coinbase shares (~$1.42 million) as of June 30. Both stocks were among Cathie Wood's ARK Investment Management's top 15 holdings at quarter-end. The focus is on Coinbase: COIN is down about 15% year-to-date but shows potential for a rally as crypto markets recover. In Q2, COIN's transaction revenue fell 22% year over year, yet market share rose to a record 10.3% of crypto trading, up 120 basis points. Catalysts include diversification into stock/ETF trading, prediction markets, derivatives, stablecoins, and blockchain infrastructure. Risks involve crypto-price dependence, volatility, and retail trading sensitivity; regulatory clarity could expand addressable market but invite competition and fee pressure. An institutional investor added a modest CRSP stake, potentially boosting sentiment but unlikely to alter fundamentals.

CRISPR Therapeutics AG (CRSP) closed at $59.03, up 1.2% as the Dow fell 0.36% and Nasdaq rose 0.45%. Over the last month, CRSP gained 2.2%, outperforming Medical sector losses (-3.65%) and the S&P 500 (+1.27%). Investors will watch the upcoming earnings, with EPS expected at -$1.06 and revenue at $9.53 million, a 971% year-over-year rise. For the full year, Zacks Consensus projects -$4.47 per share on $30.59 million in revenue, representing sizable YoY improvements. The piece notes that estimate revisions can move stock prices, and CRSP holds a Zacks Rank of #3 (Hold). The Medical-Biomedical/Genetics industry ranks in the bottom third of more than 250 industries. Near-term sentiment may shift as earnings estimates and revisions guide price movement, but no major catalysts are present.

CRISPR Therapeutics is described as a buy despite a rocky 2026, with three main drivers cited. First, progress across CRISPR-based programs and clinical data hint at upside as pivotal trials advance. Second, near-term catalysts—such as upcoming trial readouts or regulatory milestones—could lift sentiment and valuation. Third, strategic partnerships and IP positioning are viewed as enhancing growth potential and competitive standing. The piece cautions that risks remain, but the upside depends on successful execution in core programs and favorable market dynamics for gene-editing therapies. Catalysts and pipeline progress could moderately influence sentiment and valuation.

Intellia's pipeline progress is assessed for its ability to deliver long-term value while facing rivalry from CRISPR Therapeutics and others in gene editing. Intellia's pipeline updates can moderately shift competitive positioning and sentiment for CRISPR Therapeutics.

CRISPR Therapeutics could achieve major growth and market leadership over the next decade if gene editing fulfills its therapeutic promise. Fulfilling gene editing promise would drive major strategic gains and investor shifts for CRISPR Therapeutics.

CRISPR Therapeutics gains attention as CASGEVY momentum builds, though questions persist on whether the valuation is excessive. CASGEVY progress signals product traction while valuation doubts may sway short-term market views without major strategic shifts.

CRISPR Therapeutics AG is targeting CASGEVY growth while preparing for multiple year-end pipeline catalysts. CASGEVY growth targets and year-end catalysts represent major product and pipeline developments likely to alter company trajectory and investor sentiment.

CRISPR Therapeutics stock moved sharply last month on clinical pipeline updates and sector sentiment shifts affecting near-term valuation. Pipeline updates and market reactions produced moderate short-term valuation effects without evidence of fundamental long-term trajectory change.

CRISPR Therapeutics AG (CRSP) stock may surge in the final four months of 2026 due to two key factors. Speculative positive outlook on 2026 performance may moderately sway short-term investor sentiment without confirmed events.

CRISPR Therapeutics reports impressive CTX310 data yet CRSP stock appears fully valued with limited upside. Impressive CTX310 data signals meaningful progress in gene-editing pipeline for CRISPR Therapeutics.

CRISPR Therapeutics presented Phase 1a data for CTX310 at ESC Congress 2026 showing deep and durable ANGPTL3 editing with triglyceride and LDL lowering. Positive early clinical data for CTX310 advances CRISPR's lipid-editing pipeline and can shift investor outlook on pipeline progress.

CRISPR Therapeutics posted a quiet quarter as Casgevy advances and SiRNA data readouts near, per RBC. Casgevy progress plus near-term SiRNA readouts point to moderate effects on CRSP trajectory.

Vertex Pharmaceuticals posted Q2 earnings below estimates while revenues topped forecasts and 2026 sales guidance was raised. Raised VRTX sales outlook points to stronger commercial traction for the Casgevy therapy jointly developed with CRSP.

CRISPR Therapeutics AG (CRSP) stock climbed after-hours on upbeat Q2 results and plans for a busy second-half pipeline. Upbeat Q2 results and busy second-half pipeline plans signal major strategic progress likely to shift company trajectory and investor sentiment.

CRISPR Therapeutics AG posted a Q2 loss while exceeding revenue estimates. Quarterly earnings directly shape near-term investor views on financial health.

CRISPR Therapeutics provided a business update and reported second quarter 2026 financial results. Quarterly financial results and business updates can shift investor views on performance and near-term prospects.

Morgan Stanley nearly doubled its price target for CRISPR Therapeutics AG (CRSP). Analyst price target increase may boost short-term investor sentiment for CRISPR Therapeutics.

CRISPR Therapeutics AG (CRSP) is projected to surpass earnings estimates, with potential for subsequent stock price gains. Earnings beat expectations can lift short-term investor sentiment and share performance for CRISPR Therapeutics without fundamentally shifting its long-term trajectory.

Cathie Wood's ARK Invest holds a $362 million position in CRISPR Therapeutics AG backed by an underrated catalyst expected to support future growth. Prominent investor stake plus an underrated catalyst points to major positive effects on CRSP market sentiment and trajectory.

CRISPR Therapeutics' EPS projections are examined for clarity on its gene-editing commercialization path. EPS projections may moderately influence market views on commercialization progress.

CRISPR Therapeutics stock recommended for purchase based on three reasons tied to gene-editing pipeline progress and market opportunities. Bullish stock recommendation may moderately sway near-term investor sentiment without altering core operations.

New CRISPR DNA shredder technology emerges that could transform gene-editing methods with direct implications for CRISPR Therapeutics AG operations and positioning. New DNA shredder gene-editing approach may significantly shift competitive dynamics and trajectory for CRSP.

CRISPR Therapeutics AG has over 2 billion reasons for optimism from major value creation tied to its gene-editing platform, strengthening its financial and competitive outlook. Multi-billion dollar opportunities signal major strategic gains that can significantly shift CRSP trajectory and investor sentiment.

FDA clears Casgevy for children ages 2 and up, triggering surges in CRSP and VRTX stocks. Expanded FDA approval for Casgevy broadens addressable patient population and lifts CRSP outlook.

Vertex Pharmaceuticals received FDA approval for expanded use of Casgevy in sickle cell disease and transfusion-dependent beta-thalassemia. Casgevy is the CRISPR-based gene therapy co-developed by CRISPR Therapeutics and Vertex. Expanded FDA approval broadens Casgevy's addressable market and strengthens CRISPR Therapeutics' commercial prospects via its Vertex partnership.

CRISPR Therapeutics AG expands funding capacity to advance its gene editing pipeline. Funding expansion directly enables pipeline progress and strengthens long-term competitive position.

CRISPR Therapeutics holds $2.4 billion in cash and an approved drug yet trades nearly 40% below Wall Street consensus price targets. Cash reserves and approved product create valuation gap versus consensus that may shift near-term sentiment without altering core trajectory.